In recent years, a variety of glycoproteins have been approved for the treatment and diagnosis of human diseases, such as erythropoietin (EPO), granulocyte colony-stimulating factor (GCSF), β-interferon, certain cancer biomarkers, and monoclonal antibodies for public health purposes as similar biological products (SBPs) with acceptable levels of quality, safety and efficacy (Buettner et al., 2018). This evidence concerns the gene CSF3 and cancer.